CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
Gene expression mRNA of IgG anti-spikeother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06597370
NCT06597370N/ACompleted
CompareCT.gov

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population: mRNA Expression for IgG Anti-spike

National Polytechnic Institute, Mexico·observational·Posted Sep 19, 2024·Updated Oct 4, 2024

In Brief

An observational study evaluating Gene expression mRNA of IgG anti-spike for COVID-19 Vaccine. Completed, enrolled 80 participants across 1 site.

Detailed Summary

To determine the gene expression of anti-spike IgG through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Vaccine
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 19, 2024
Enrollment StartSep 1, 2021
Primary CompletionDec 20, 2021
Study CompletionDec 21, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.8 years ago

Interventions

Gene expression mRNA of IgG anti-spikeother

b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule. c) Sample processing: * tRNA extraction from all samples. * cDNA synthesis * Real time PCR performance.